# A Study to Assess if a Medicine Called Bamlanivimab is Safe and Effective in Reducing Hospitalization Due to COVID-19

> **NCT04796402** · PHASE4 · UNKNOWN · sponsor: **Fraser Health** · enrollment: 576 (estimated)

## Conditions studied

- Covid19

## Interventions

- **BIOLOGICAL:** Bamlanivimab
- **OTHER:** Standard of Care

## Key facts

- **NCT ID:** NCT04796402
- **Lead sponsor:** Fraser Health
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-17
- **Primary completion:** 2021-06-07
- **Final completion:** 2021-12-31
- **Target enrollment:** 576 (ESTIMATED)
- **Last updated:** 2021-08-26

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04796402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04796402, "A Study to Assess if a Medicine Called Bamlanivimab is Safe and Effective in Reducing Hospitalization Due to COVID-19". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04796402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*